VHPB technical meeting: Viral hepatitis treatment as prevention (TAP)

Meeting objectives:

Viral hepatitis treatment as prevention (TAP)

  • Give an overview of the scientific evidence to use treatment during pregnancy to avoid perinatal transmission of hepatitis B and C
  • Discuss the new perinatal WHO recommendations on hepatitis B Prevention of mother to child transmission of hepatitis B focusing on the use of treatment during pregnancy
  • Discuss the possible impact of treatment as prevention of perinatal transmission on the triple elimination goals.
  • Review scientific evidence of TAP to avoid hepatitis B and C infections in risk populations,
  • Discuss Real-life data of TAP project in different risk groups
  • Review scientific evidence for treatment of all hepatitis B positives to prevent disease progression,
  • Discuss if treatment to prevent disease progression could be a public health recommendation

Background document TAP I (Pdf, kB)

Background document TAPII (Pdf, kB)
 

 

Thursday 15th of October 2020

PART 1 - TREATMENT AS PREVENTION (TAP) HEPATITIS C IN RISK GROUPS

Welcome and opening of the meeting
Chairs: Mojca Matitic & Pierre Van Damme

16:30 - 16:50     Welcome and opening of the meeting (Pdf, 324 kB)
 Introduction of the VHPB Board & participants

1. Hepatitis treatment as prevention in risk groups

Session 1.1: Real-life data of TAP in different risk groups 

16:50 - 17:10     Treatment as prevention in risk groups: an overview  (Pdf, 3.637 kB)
Mojca Matitic

17:10 - 18:25     Treat all or Treatment as prevention in Risk groups

17:10 - 17:25     Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study (Pdf, 505 kB) 
Adam Trickey

PWID - Model of care and outcomes in PWID

17:25 - 17:40     Iceland  Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. (Pdf, 2.069 kB)
Magnus Gottfredsson

17:40 - 17:55     Scotland Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). (Pdf, 1.905 kB)
Matthew Hickman

Prisoners – model of care and outcomes in PWID and prisoners (No speaker, included in the review of Mojca Maticic).

17:55 - 18:10     MSM - Model of care and outcomes in MSM

The Netherlands – Declining Hepatitis C Virus (HCV) Incidence in Dutch Human Immunodeficiency Virus-Positive Men Who Have Sex With Men After Unrestricted Access to HCV
Anders Boyd

17:10 - 18:25     Lessons Learned from HIV TAP program
Treatment as Prevention: Should Hepatitis C Learn the Lessons from HIV? (Pdf, 2.128 kB)
José Vincent Fernandez-Montero

Session 1.2: Groups discussion: hepatitis treatment as prevention

18:30 - 19:30     Groups discussion: hepatitis TAP be included in public health guidelines and recommendations

Questions to be answered:

1. Is there enough scientific evidence to include TAP in hepatitis prevention guidelines in all risks group or in some?
    Chair: Thomas Vanwolleghem

2. Should TAP be included in the national hepatitis elimination plan? (responsibilities – resources)
    Chair: Daniel Lavanchy

3. Should TAP in risks groups be included in WHO’s targets to achieve  hepatitis Elimination by 2030? Is Micro elimination the way to go?
    Chair: Antons Mozalevskis

Report - TAP in risk groups

 

Thursday 22 October 2020

PART II - TREATMENT AS PREVENTION (TAP)

2. Treatment as to prevent perinatal mother to child transmission (MTCT) of hepatitis B – Liver disease progression

16:30 - 16:45      Welcome and opening of the meeting (Pdf, 342 kB)
Introduction of the VHPB Board & participants

2.1. Treatment as to prevent perinatal mother to child transmission (MTCT) of hepatitis B

Session 2.1.1: Overview TAP in MTCT
Chairs: Antons Mozalevskis and Mark Kane

Conclusions of Pre-recorded presentation

16:45 - 16:55     Who to treat
Prevention of perinatal hepatitis B virus transmission. (135.455 MP4)
Kelvin Cheung

16:55 - 17:10     Efficacy and Safety of TAP In pregnancy

Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. (Pdf, 2.722 kB)
Yusuke Shimakawa

Cost-effectiveness (see later)

Session 2.1.2: Guidelines and recommendation for TAP in MTCT

17:10 - 17:25     Lessons learnt from Treatment as prevention in real world (Western Pacific)
Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus - Western Pacific Region, 2005-2017. (350.248 MP4)
Rania Tohme

17:25 - 17:40      New recommendations on HBV prevention of mother-to-child transmission and the use of NUCs as an additional PMTCT intervention. (Pdf, 1.303 kB)
Antons Mozalevskis 

17:40 - 17:55     Cost-effectiveness
Mother-to-child transmission of hepatitis B: What more needs to be done to eliminate it around the world.
Shevanthi Nayagam

Session 2.1.3: Groups discussion: hepatitis treatment as prevention  

17:55 - 18:35     Groups discussion: hepatitis TAP be included in guidelines and recommendations

Questions to be answered:

  1. Are the new WHO recommendations on HBV prevention of perinatal transmission, including TAP and added value to reach the hepatitis elimination goals?
    Chair: Vana Papaevangelou
     
  2. In low endemic countries (Europe) should we focus on Screening and TAP in pregnant women or on Birth dose vaccination or both?
    Chair: Silvia Bino

2.2. Treatment to prevent liver disease progression

Session 2.2.1: Overview treatment to prevent liver disease progression in HbsAg positives

18:35 - 18:50     Conclusions of Pre-recorded presentation

Evidence for application of treatment to prevent liver disease progression in hepatitis B. (Pdf, 1.544 kB)
Homie  Razavi

Country example Uzbekistan
Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model - Tashkent, Uzbekistan. (19.883 MP4)
Shakhlo Sadirova

Session 2.2.2: Groups discussion: hepatitis treatment as prevention liver  disease progression

18:50 - 19:30    Groups discussion: hepatitis TAP be included in guidelines and recommendations

Questions to be answered:

  1. Is there enough scientific evidence to recommend treatment to prevent liver disease progression in the context of public health
    Chair: John Ward
     
  2. Is treatment for all patients who tested positive for Hepatitis B feasible (resources)
    Chair: Daniel Shouval

 

The report of the meeting will be availabe soon. 

 
Tags: 
meeting